Drug and alcohol dependence reports最新文献

{"title":"Social media for recovery support for people with substance use disorder. A cross-sectional study of use patterns and motivations","authors":"Chanda Phelan ,&nbsp;Abby P.M. Katz ,&nbsp;Jennifer E. Merrill ,&nbsp;Kristina M. Jackson ,&nbsp;Tyler B. Wray","doi":"10.1016/j.dadr.2025.100331","DOIUrl":"10.1016/j.dadr.2025.100331","url":null,"abstract":"<div><h3>Objective</h3><div>This study examined the use of social media for recovery support among individuals with substance use disorder (SUD) with past-year treatment attendance and tested whether demographic and SUD history factors were associated with use of social media for recovery support.</div></div><div><h3>Method</h3><div>Participants (N = 255; 45 % female, 85 % white, mean age = 41.4 [9.6]) recently treated for SUD completed an online survey. The survey gathered demographics, SUD histories, and social media use data. We report descriptive statistics and logistic regression models testing relationships between social media for recovery support and individual factors.</div></div><div><h3>Results</h3><div>Forty percent of participants used social media for recovery support, and most believed it beneficial. Being female increased use likelihood (OR = 2.56, 95 % CI [1.49, 4.46]), while older age (50 +) was associated with lower use likelihood than young adults (18−35) (OR = 0.35, 95 % CI [0.14, 0.84]). Social media was used primarily to build support systems and follow recovery-related content. Most found support forums on their own, and engaged with the groups for meaningful amounts of time (<u>&gt;</u>weekly, <u>&gt;</u>15<!--> <!-->minutes).</div></div><div><h3>Conclusions</h3><div>Results highlight how common it is to use social media for recovery support. Given the sparse evidence on its efficacy, more research is urgently needed to establish whether recovery support forums on social media convey actual benefits, and how to shape one’s digital environment to maximize those benefits.</div></div>","PeriodicalId":72841,"journal":{"name":"Drug and alcohol dependence reports","volume":"15 ","pages":"Article 100331"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143864933","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long acting injectable buprenorphine: Perspectives from service-users, staff and stakeholders","authors":"Rebecca Fish ,&nbsp;Céu Mateus ,&nbsp;Hannah Maiden ,&nbsp;Euan Lawson ,&nbsp;Mark Limmer","doi":"10.1016/j.dadr.2025.100328","DOIUrl":"10.1016/j.dadr.2025.100328","url":null,"abstract":"<div><h3>Introduction</h3><div>Long-acting injectable buprenorphine (LAIB) is a relatively novel pharmacological treatment for people with opioid dependence. Despite growing qualitative evidence, there is limited research on practitioner insights, and effectiveness of LAIB in a community setting.</div></div><div><h3>Methods</h3><div>Thirteen service-users (11 currently prescribed LAIB), 6 practitioners, and 4 stakeholders (public health workers) took part in semi-structured interviews (n = 23) to glean their perspectives on LAIB. They were recruited through a community drug treatment service in the NW of England. The interview schedule was informed by previous literature and co-produced with a peer worker with lived experience of drug recovery treatment. Transcripts were analysed thematically by the research team.</div></div><div><h3>Results</h3><div>Four major themes were identified from the interviews: A change of focus; challenges; wrap-around support; and target groups.</div></div><div><h3>Discussion</h3><div>Our findings support existing evidence around the individual benefits to service-users such as changes to lifestyle and reduction of stigma, as well as challenges such as the need for wrap-around support and accessible information. We found that commissioning considerations such as geographical inequalities and the need for multi-service collaboration are important in this setting.</div></div><div><h3>Conclusions</h3><div>LAIB treatment works well for many people in a community context that offers significant wrap-around support to service-users. The novelty of this research lies in bringing together the views of practitioners and stakeholders as well as treatment/service beneficiaries in evaluating the introduction of LAIB in a community service.</div></div>","PeriodicalId":72841,"journal":{"name":"Drug and alcohol dependence reports","volume":"15 ","pages":"Article 100328"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143791994","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The psychostimulant drug, fenethylline (captagon): Health risks, addiction and the global impact of illicit trade","authors":"Matthew Chidozie Ogwu ,&nbsp;Matěj Malík ,&nbsp;Pavel Tlustoš ,&nbsp;Jiří Patočka","doi":"10.1016/j.dadr.2025.100323","DOIUrl":"10.1016/j.dadr.2025.100323","url":null,"abstract":"<div><div>Fenethylline (street name, captagon) is a synthetic amphetamine-type stimulant that is emerging as a significant public health and security concern, particularly in the Middle East. This systematic review synthesizes original research articles, epidemiological studies, systematic reviews, policy analyses, and case reports to provide a comprehensive analysis of fenethylline’s health impacts, addiction potential, and dynamics of illicit trade. Initially developed for therapeutic use, fenethylline illicit production and use have escalated, raising concern about its physiological, psychological, and socio-economic impacts. This stimulant profoundly affects the central nervous system, enhancing wakefulness, concentration, and physical stamina while inducing euphoria. These effects come at the cost of serious adverse health outcomes, particularly with prolonged or heavy use, including cardiovascular complications, neurological damage, and addiction. The dependence-forming nature of captagon contributes to escalating substance use disorders, impacting healthcare systems. Beyond its biomedical implications, fenethylline trafficking has become a global issue, with supply chains deeply intertwined with politically unstable regions where illicit economies thrive. The geopolitical dimensions of captagon’s trade amplify its global security threat, influencing international relations and regional stability. This paper underscores the urgent need for systematic data collection and coordinated efforts to regulate illicit fenethylline production and distribution. Strategies such as improved surveillance, public health interventions, and international cooperation are essential to mitigate its escalating risks. Addressing this issue requires a multidisciplinary approach, integrating public health, law enforcement, and policy development to curb its impact on global health and security.</div></div>","PeriodicalId":72841,"journal":{"name":"Drug and alcohol dependence reports","volume":"15 ","pages":"Article 100323"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143594019","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Trends in motives for attempts to reduce alcohol consumption among risky adult drinkers in England: A representative population survey, 2017–2024","authors":"Dimitra Kale ,&nbsp;Vera Buss ,&nbsp;Melissa Oldham ,&nbsp;Jamie Brown ,&nbsp;Lion Shahab ,&nbsp;Sarah Jackson","doi":"10.1016/j.dadr.2025.100340","DOIUrl":"10.1016/j.dadr.2025.100340","url":null,"abstract":"<div><h3>Background</h3><div>Understanding the motives for reducing alcohol consumption, how they differ among various population groups, and how they have evolved over time is crucial for designing effective public health interventions. This study estimated time trends in motives for attempts to reduce alcohol consumption among risky adult drinkers in England between 2017 and 2024 and explored differences by sociodemographics and alcohol consumption levels.</div></div><div><h3>Methods</h3><div>Data came from a nationally representative survey (Alcohol Toolkit Study), assessing 11,974 risky adult drinkers (mean [Standard Deviation] age= 45.8 [15.7] years, 60.1 % men) who made a past-year reduction attempt between January/2017 and August/2024. Participants reported factors motivating their most recent attempt (not mutually exclusive). We estimated time trends in the proportion of attempts to reduce alcohol consumption motivated by health concerns, cost, social factors (i.e., peer influence/support) and health professional advice, and calculated prevalence ratios (PRs) to compare changes in prevalence across the whole time series.</div></div><div><h3>Results</h3><div>Over the time series, there was a small increase in the proportion of attempts motivated by health concerns (70.5–76.8 %; PR=1.09, 95 %CI1.01–1.18). Attempts motivated by cost and social factors nearly doubled (10.7–20.2 %; PR=1.89, 95 %CI1.37–2.60; 13.3–25.5 %; PR=1.92, 95 %CI1.46–2.52, respectively). Attempts driven by health professional advice increased (4.4–7.0 %; PR=1.57, 95 %CI0.96–2.57). Women, individuals from less advantaged social grades and with AUDIT-C 5–7 exhibited more pronounced changes in the proportion of attempts motivated by health concerns. Cost was a more consistent driver of attempts for those aged≥ 65.</div></div><div><h3>Conclusions</h3><div>Health concerns remain the most common motive for attempts to reduce alcohol consumption, but the proportion of attempts motivated by cost and social factors nearly doubled over the study period. These findings suggest the need for public health interventions that consider both economic and social influences alongside health concerns to better support alcohol reduction.</div></div>","PeriodicalId":72841,"journal":{"name":"Drug and alcohol dependence reports","volume":"15 ","pages":"Article 100340"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143922131","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Substance use and mental health characteristics among pregnant individuals with medical and non-medical benzodiazepine use early in pregnancy","authors":"Ayesha C. Sujan ,&nbsp;Natalie E. Slama ,&nbsp;Brian T. Bateman ,&nbsp;Deborah Ansley ,&nbsp;Carley Castellanos ,&nbsp;Kelly C. Young-Wolff","doi":"10.1016/j.dadr.2025.100345","DOIUrl":"10.1016/j.dadr.2025.100345","url":null,"abstract":"<div><h3>Background</h3><div>Research to date evaluating the safety of benzodizapine use during pregnancy has shown mixed results and has relied on self-report or filled prescription data, which are unlikely to capture non-medical use and, consequently, could bias results. Therefore, research on non-medical benzodiazepine use during pregnancy is needed.</div></div><div><h3>Methods</h3><div>The present study used data from a large, healthcare system with universal screening for prenatal substance use via urine toxicology tests and information on filled prescriptions. We first evaluated the prevalence of pregnancies with non-medical benzodiazepine use (positive urine toxicology test and no filled prescriptions in the past year) and medical benzodiazepine use (positive urine toxicology test and <u>&gt;</u>1 filled prescription in the past year). We also evaluated the presence of co-occurrence of substance use and mental health conditions among these pregnancies.</div></div><div><h3>Results</h3><div>Our results showed that benzodiazepine use during early pregnancy was rare (&lt;1 % had a positive toxicology test). However, more than one-third of those with a positive toxicology test did not have a filled prescription (i.e., had non-medical use) We also found similar rates of substance use and mental health conditions among pregnancies with medical and non-medical benzodiazepine use.</div></div><div><h3>Conclusion</h3><div>Our results suggest that research relying on prescription data alone and the medical system may be missing pregnant individuals using benzodiazepines. This points to a need for additional measures and screenings (e.g., urine toxicology tests) in both research and clinical settings. Our findings also underscore a need for additional services for pregnant individuals with both medical and non-medical benzodiazepine use.</div></div>","PeriodicalId":72841,"journal":{"name":"Drug and alcohol dependence reports","volume":"15 ","pages":"Article 100345"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144124189","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Influence of SSRI and SNRI co-prescription on benzodiazepine prescription trajectories","authors":"Kerry L. Kinney ,&nbsp;Eliseu da Cruz Moreira-Junior ,&nbsp;Laís F. Berro ,&nbsp;Matthew C. Morris ,&nbsp;James K. Rowlett","doi":"10.1016/j.dadr.2025.100325","DOIUrl":"10.1016/j.dadr.2025.100325","url":null,"abstract":"<div><h3>Purpose</h3><div>This study examined whether co-prescription of selective serotonin reuptake inhibitors (SSRIs) or serotonin or norepinephrine reuptake inhibitors (SNRI)s with benzodiazepines is associated with differences in benzodiazepine prescriptions both within individual patients over time and between patients.</div></div><div><h3>Methods</h3><div>We analyzed deidentified electronic health records of patients prescribed a benzodiazepine between 2020 and 2022 (<em>N</em> = 847). Patients were categorized into three groups: those co-prescribed an SSRI, those co-prescribed an SNRI, and those not co-prescribed an SSRI or SNRI.</div></div><div><h3>Results</h3><div>Individuals co-prescribed an SSRI (<em>M</em>=6.63) or an SNRI (<em>M</em>=8.31) had more benzodiazepine prescription encounters than those who were not co-prescribed an SSRI/SNRI (<em>M</em>=5.08). Individuals co-prescribed an SSRI or SNRI also received a higher maximum benzodiazepine dosage than those who were not co-prescribed an SSRI/SNRI (SSRI <em>M</em>=2.41; SNRI <em>M</em>=2.30; No SSRI/SNRI <em>M</em>=1.91 diazepam milligram equivalent defined daily doses). Multilevel models indicated the SSRI co-prescription group received a higher initial benzodiazepine dosage (<em>b</em>=0.394), but showed no significant change in benzodiazepine dosage over time. When controlling for demographic and clinical correlates of benzodiazepine prescriptions, those who were not co-prescribed an SSRI showed an increase in benzodiazepine dose over time (<em>b</em>=0.075). Multilevel models revealed no relationship between SNRI co-prescription and starting benzodiazepine dosage or change in benzodiazepine dosage over time. An anxiety disorder diagnosis, younger age, and non-Black/African American race were associated with higher benzodiazepine dose.</div></div><div><h3>Conclusions</h3><div>Individuals who are co-prescribed an SSRI/SNRI may be vulnerable to longer treatment durations and higher prescribed doses of benzodiazepines, raising concerns about risk for dependence among individuals receiving combined benzodiazepine and SSRI/SNRI treatment.</div></div>","PeriodicalId":72841,"journal":{"name":"Drug and alcohol dependence reports","volume":"15 ","pages":"Article 100325"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143698125","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring the impact of a medication adherence intervention on recovery and mental health outcomes: A secondary analysis of the MAT-PLUS pilot RCT","authors":"Kevin Wenzel ,&nbsp;Julia Thomas ,&nbsp;Jennifer Carrano ,&nbsp;Jennifer Stidham ,&nbsp;Marc Fishman","doi":"10.1016/j.dadr.2025.100346","DOIUrl":"10.1016/j.dadr.2025.100346","url":null,"abstract":"<div><h3>Background</h3><div>Substance use disorders (SUDs) including opioid use disorder (OUD) and alcohol use disorder (AUD) contribute to significant morbidity and mortality in the United States. Pharmacotherapy treatment, including extended-release naltrexone (XR-NTX), is underutilized in large part due to poor treatment retention. The MAT-PLUS (Medication Adherence Therapy: Psychosocial Leverage Using a Significant other) intervention combines assertive outreach, significant other involvement, and low-barrier access to medicine to improve retention on XR-NTX, and has shown promising results in a pilot RCT. <em>Methods:</em> This report explored secondary outcomes from the MAT-PLUS pilot RCT (NCT03567356) to determine the impact of the intervention on recovery experience as measured by the Recovery Assessment Scale (RAS) and mental health indicators as measured by the patient health questionnaire- somatic, anxiety, depression scale (PHQ-SADS) on <em>N</em> = 41 participants. <em>Results:</em> A series of repeated measures mixed ANOVAs did not find evidence of an effect of the MAT-PLUS intervention on these outcomes. Although total RAS scores did not improve over time in either condition, an independent samples t-test at the post-intervention follow up suggested some evidence of a possible treatment effect on two subscales of the RAS: 1) Not being dominated by symptoms and 2) Goal and success orientation. <em>Discussion:</em> The results of this study suggest that mental health symptoms are attenuated during treatment, whether usual care or the MAT-PLUS intervention, but that recovery indicators did not improve with treatment. Approaches to SUD care, including the MAT-PLUS intervention, should be refined to target improvements in recovery capital in addition to focusing on symptom reduction.</div></div>","PeriodicalId":72841,"journal":{"name":"Drug and alcohol dependence reports","volume":"15 ","pages":"Article 100346"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144124190","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Characterizing withdrawal from long-acting injectable buprenorphine: An observational case series","authors":"Victoria Hayes ,&nbsp;Llewellyn Mills ,&nbsp;Gaye Byron ,&nbsp;Carolyn Stubley ,&nbsp;Eleanor Black ,&nbsp;Benjamin T. Trevitt ,&nbsp;Andrew A. Somogyi ,&nbsp;Arshman Sahid ,&nbsp;Nicholas Lintzeris","doi":"10.1016/j.dadr.2025.100329","DOIUrl":"10.1016/j.dadr.2025.100329","url":null,"abstract":"<div><h3>Introduction</h3><div>Long-acting injectable buprenorphine (LAIB) products are being increasingly used to treat patients with opioid dependence. Limited data is available on the severity or timespan (time to onset, peak, duration) of withdrawal signs and symptoms following discontinuation of treatment.</div></div><div><h3>Methods</h3><div>Participants aiming to discontinue long-term LAIB treatment commenced the study on the day of their final dose of Buvidal® 64<!--> <!-->mg Monthly. Participants were monitored with weekly assessments of withdrawal severity, cravings, general health, and patient experience measures for up to 16 weeks after last dose.</div></div><div><h3>Results</h3><div>Fifteen participants – those who remained for at least four weeks after the last LAIB dose – were included in the study. There was minimal increase in withdrawal severity over the study period, with an average peak Clinical Opioid Withdrawal Scale score of 4.8 ± 2.7, occurring at a median of 6 weeks (IQR 4–7.5) after the last LAIB dose. Cravings scores were generally low but increased gradually over the 16-week study period. There was no deterioration in physical or mental health scores, and participants reported high levels of satisfaction with the withdrawal experience. Ten participants used rescue medications, predominately in weeks 5 or 6 after the last dose.</div></div><div><h3>Discussion and conclusions</h3><div>Participants (last dose of Buvidal® 64<!--> <!-->mg Monthly) experienced minimal or mild withdrawal signs and symptoms, usually peaking in severity between 5 and 8 weeks after the last dose. These results are encouraging, however clinical trials comparing withdrawal outcomes between LAIB, sublingual buprenorphine (SL BPN) and methadone are required to inform treatment planning.</div></div>","PeriodicalId":72841,"journal":{"name":"Drug and alcohol dependence reports","volume":"15 ","pages":"Article 100329"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143823754","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"An exploratory study on the use of sexually transmitted infection prevention and contraception methods among women and men who use unprescribed opioids","authors":"Joy D. Scheidell ,&nbsp;Sophia Dakoulas ,&nbsp;Teresa Chueng ,&nbsp;Katrina Ciraldo ,&nbsp;Belén Hervera ,&nbsp;Muthoni Mahachi ,&nbsp;Luther C. Elliott ,&nbsp;Alex S. Bennet","doi":"10.1016/j.dadr.2025.100337","DOIUrl":"10.1016/j.dadr.2025.100337","url":null,"abstract":"<div><h3>Introduction</h3><div>The dual epidemics of sexually transmitted infections (STIs) and unprescribed opioid use persist globally, including in the United States. This study addresses gaps in STI prevention and contraception among people who use unprescribed opioids in New York City (NYC), focusing on both men and women.</div></div><div><h3>Methods</h3><div>We conducted a cross-sectional substudy from November 2021-August 2022 assessing sexual health with a one-time survey within a longitudinal cohort study among people who use unprescribed opioids in NYC that collected baseline data during 2019–2020. We measured sociodemographic characteristics, substance use history, sexual partnerships and STI prevention and contraception categorized as providing effective prevention versus none/ineffective. We estimated the prevalence of lack of effective STI prevention and contraception and potential correlates among males and females.</div></div><div><h3>Results</h3><div>The analytic sample included 108 participants (54 % male, 46 % female) with a mean age of 46 years. No/ineffective STI prevention was most common among reproductive-age females (81 %) and lowest among males (67 %) and no/less effective contraception was reported by approximately 90 % of participants. No/ineffective STI prevention and contraception were differentially associated with factors such as sexual partnerships, substance use treatment, and healthcare utilization among males and females.</div></div><div><h3>Discussion</h3><div>Findings highlight the need for improved provision of effective STI and pregnancy prevention methods for both men and women who use drugs. There is a critical need to expand access to sexual and reproductive health services for people who use drugs, including integrating these services into diverse healthcare and drug-service settings.</div></div>","PeriodicalId":72841,"journal":{"name":"Drug and alcohol dependence reports","volume":"15 ","pages":"Article 100337"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143899531","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of recent stimulant use on treatment outcomes amongst individuals initiating medications for opioid use disorders: Secondary analysis of a multisite randomized controlled trial","authors":"Cari Coles ,&nbsp;Courtney Batts ,&nbsp;Joanne Bae ,&nbsp;Gabriela León ,&nbsp;Alex Schmidt ,&nbsp;Sterling M. McPherson ,&nbsp;Crystal L. Smith ,&nbsp;André C. Miguel","doi":"10.1016/j.dadr.2025.100330","DOIUrl":"10.1016/j.dadr.2025.100330","url":null,"abstract":"<div><h3>Introduction</h3><div>Illicit stimulant use among individuals initiating medication for opioid use disorder (MOUD) has significantly increased over the past decade. Co-use of these substances is associated with increased risk of mortality as well as worse treatment outcomes. This study examines the potential predictive role of stimulant urinalysis result at baseline on treatment retention and opioid and stimulant use outcomes amongst individuals initiating MOUD treatment.</div></div><div><h3>Methods</h3><div>This is a cross-sectional secondary analysis of data from a multi-site randomized clinical trial (CTN-0027). A total of 1269 individuals were randomized to receive 24 weeks of buprenorphine (n = 740) or methadone (n = 529) treatment across nine sites. Multiple linear and logistic regressions were conducted to determine the impact of baseline stimulant urinalysis results on treatment retention, and stimulant and opioid use outcomes.</div></div><div><h3>Results</h3><div>Individuals initiating MOUD with a stimulant negative urinalysis result at baseline submitted more negative stimulant (ꞵ=7.8; 95 % CI 6.8–8.7) and opioid (ꞵ=2.8; 95 % CI 1.8–3.8) urinalyses during treatment, were more likely to complete treatment (aOR=1.4; 95 % CI 1.1–1.7), and had better outcomes at six-month follow-up, measured as negative urinalysis for stimulant (aOR=5.3; 95 % CI 3.6–7.7), and opioid (aOR=1.8; 95 % CI 1.3–2.6).</div></div><div><h3>Conclusion</h3><div>Baseline stimulant use is associated with worse MOUD treatment outcomes, underscoring the need for novel integrated interventions designed to address opioid and stimulant co-use.</div></div>","PeriodicalId":72841,"journal":{"name":"Drug and alcohol dependence reports","volume":"15 ","pages":"Article 100330"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143820389","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}